Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bolt Biotherapeutics, Inc.
Roswell Park Cancer Institute
Mayo Clinic
Molecular Templates, Inc.
Taizhou Mabtech Pharmaceutical Co.,Ltd
Fate Therapeutics
Nektar Therapeutics
Celgene
Calithera Biosciences, Inc
Presage Biosciences
Incyte Corporation
Washington University School of Medicine
MultiVir, Inc.
Celgene